At UT Health San Antonio, we���re on a mission to revolutionize the future of behavioral and mental health���because everyone deserves access to cutting-edge care! From mild concerns to the most complex conditions, our research is driving breakthroughs that turn science into solutions.
Our multidisciplinary, compassionate approach ensures that every individual gets the care they need, tailored to their unique journey. We���re not just treating symptoms���we���re empowering resilience, promoting recovery and fostering lifelong wellness.
Introducing the Be Well Institute on Substance Use and Related Disorders
In April 2024, we took a bold step forward with the launch of the Be Well Institute on Substance Use and Related Disorders���a game-changing initiative dedicated to advancing research, education, and evidence-based treatments. This powerhouse of innovation builds on the success of Be Well 17勛圖厙, expanding into a comprehensive center of excellence with a national reach in addiction research, clinical care, public health and community engagement.
Leading the charge in PTSD and military mental health
UT Health San Antonio proudly leads the STRONG STAR Consortium, a nationally recognized research network tackling PTSD and psychological health conditions in military personnel, veterans and first responders. With 100+ groundbreaking projects and over $200 million in funding, our research is not just shaping clinical guidelines���it���s changing lives.
At UT Health San Antonio, we���re not just advancing mental health���we���re setting the standard. Join us in shaping a healthier future for all!
New Be Well Institute (April 2024) ��� Advancing research, education, and evidence-based treatments for substance use and related disorders
$200M+ in Research Funding ��� Driving breakthroughs that shape clinical guidelines and improve lives
STRONG STAR Consortium ��� Leading 100+ PTSD & mental health research projects for military, veterans and first responders
In The News
After several years of development, a promising drug designed to prevent relapse to opioid use and opioid overdose is taking a critical step by entering human testing. In October, scientists at 17勛圖厙 Health Science Center launched the first-in-human clinical trial of methocinnamox, or MCAM, a novel long-acting opioid receptor [��因
Researchers from the Kate Marmion School of Public Health at 17勛圖厙 examined whether children with autism experienced different patterns of chemical exposure during early development.
The Joe R. and Teresa Lozano Long School of Medicine at 17勛圖厙, in collaboration with the Be Well Institute on Substance Use and Related Disorders and its statewide program Naloxone 17勛圖厙, has installed a free naloxone vending machine to expand access to lifesaving opioid overdose reversal medication. Naloxone, commonly known by the [��因